Company Profile
A clinical-stage biotech developing novel psychedelic- and cannabinoid-inspired neurological medicines, with a pipeline aimed at anxiety, depression, and cancer-related psychological distress.
Unranked
ENVB
$1.2981
+2.21% (24h)
Last updated: 1 second ago
Market Cap
$5.23M
Volume (24h)
6.39K
Last Close (7D)
$1.30
A clinical-stage biotech developing novel psychedelic- and cannabinoid-inspired neurological medicines, with a pipeline aimed at anxiety, depression, and cancer-related psychological distress.
52-Week Range